Coegin Pharma

On 18 December, Coegin Pharma AB invites to a Q&A session where Jens Eriksson, Lars Bukhave Rasmussen, and John Zibert from the company's management team will answer questions about the hair growth project Follicopeptide and provide an update on the project's progress.

The Q&A is open to everyone and will be held digitally via Microsoft Teams. To make the Q&A accessible to both Swedish and international participants, two separate sessions will be offered:

• In Swedish: 14:30-15:00 CET
• In English: 18:00-18:30 CET | 12:00-12:30 ET

To participate, you need to register and submit your questions in advance by 17:00 CET | 11:00 ET on 17 December via the links below.

Swedish session: https://events.teams.microsoft.com/event/d637ba8f-26fc-4128-abdc-ad1ba3479f47@feafb1b6-cfee-4116-99ee-75f027382950

International session: https://events.teams.microsoft.com/event/3836ed93-8abc-4ef2-8222-b8ad243c7c03@feafb1b6-cfee-4116-99ee-75f027382950

You do not need to have Microsoft Teams installed to participate, as you can join directly via your web browser.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction, leukemia and skin cancer. Coegin Pharma is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.

Coegin Pharma's share is listed on NGM Nordic SME and is dual-listed on Börse Stuttgart. The company has a registered office in Lund, Sweden. 

For more information, please visit: coeginpharma.com/en